FindTrial
Sign In

Toripalimab + Chemotherapy

DRUG2 trials

Sponsors

Shanghai Pulmonary Hospital, Shanghai, China, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

HPV (Human Papillomavirus)-Associated CarcinomaHPV 16 Positive Oropharyngeal Tumors (OPC)Head and Neck CancerLaryngeal CancerOral Cavity CancerOropharyngeal CancerSinonasal Squamous Cell CarcinomaSkull Base Tumors

Phase 2

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor
NCT04667793
Shanghai Pulmonary Hospital, Shanghai, ChinaThymic Epithelial Tumor
Start: 2021-01-31End: 2024-04-30Target: 15Updated: 2023-04-04
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
RecruitingNCT07209189
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsHead and Neck Cancer, HPV 16 Positive Oropharyngeal Tumors (OPC), HPV (Human Papillomavirus)-Associated Carcinoma +6
Start: 2026-02-18End: 2030-12-01Target: 75Updated: 2026-04-23